Bellerophon Therapeutics Inc
NASDAQ:BLPH
Balance Sheet
Balance Sheet Decomposition
Bellerophon Therapeutics Inc
Current Assets | 5m |
Cash & Short-Term Investments | 4.4m |
Other Current Assets | 597k |
Current Liabilities | 1.3m |
Accounts Payable | 612k |
Accrued Liabilities | 644k |
Balance Sheet
Bellerophon Therapeutics Inc
Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | ||
---|---|---|---|---|---|---|---|---|---|---|---|
Assets | |||||||||||
Cash & Cash Equivalents |
0
|
17
|
6
|
14
|
29
|
17
|
10
|
48
|
25
|
7
|
|
Cash Equivalents |
0
|
17
|
6
|
14
|
29
|
17
|
10
|
48
|
25
|
7
|
|
Short-Term Investments |
0
|
0
|
18
|
6
|
3
|
0
|
0
|
0
|
0
|
0
|
|
Other Current Assets |
2
|
11
|
5
|
6
|
4
|
1
|
1
|
1
|
1
|
1
|
|
Total Current Assets |
2
|
28
|
29
|
27
|
36
|
17
|
10
|
48
|
25
|
8
|
|
PP&E Net |
2
|
2
|
2
|
1
|
1
|
1
|
2
|
2
|
1
|
0
|
|
PP&E Gross |
2
|
2
|
2
|
0
|
0
|
1
|
2
|
2
|
1
|
0
|
|
Accumulated Depreciation |
1
|
1
|
2
|
0
|
0
|
2
|
2
|
2
|
2
|
3
|
|
Other Long-Term Assets |
0
|
4
|
7
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Total Assets |
4
N/A
|
33
+817%
|
38
+15%
|
30
-23%
|
37
+24%
|
18
-50%
|
13
-29%
|
50
+283%
|
27
-47%
|
8
-70%
|
|
Liabilities | |||||||||||
Accounts Payable |
1
|
0
|
2
|
3
|
4
|
3
|
3
|
4
|
1
|
1
|
|
Accrued Liabilities |
13
|
9
|
6
|
4
|
3
|
5
|
4
|
7
|
4
|
4
|
|
Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Other Current Liabilities |
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Total Current Liabilities |
14
|
10
|
8
|
7
|
7
|
8
|
8
|
10
|
5
|
5
|
|
Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Other Liabilities |
5
|
0
|
0
|
5
|
32
|
7
|
2
|
2
|
0
|
0
|
|
Total Liabilities |
19
N/A
|
10
-46%
|
8
-23%
|
12
+45%
|
39
+236%
|
15
-63%
|
10
-34%
|
12
+26%
|
5
-56%
|
5
+3%
|
|
Equity | |||||||||||
Common Stock |
0
|
77
|
0
|
0
|
1
|
1
|
0
|
0
|
0
|
0
|
|
Retained Earnings |
177
|
54
|
101
|
124
|
179
|
177
|
190
|
214
|
232
|
252
|
|
Additional Paid In Capital |
0
|
0
|
131
|
142
|
176
|
180
|
193
|
253
|
254
|
255
|
|
Other Equity |
161
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Total Equity |
16
N/A
|
23
N/A
|
30
+32%
|
18
-41%
|
3
N/A
|
4
N/A
|
4
-7%
|
38
+965%
|
22
-43%
|
3
-88%
|
|
Total Liabilities & Equity |
4
N/A
|
33
+817%
|
38
+15%
|
30
-23%
|
37
+24%
|
18
-50%
|
13
-29%
|
50
+283%
|
27
-47%
|
8
-70%
|
|
Shares Outstanding | |||||||||||
Common Shares Outstanding |
1
|
1
|
1
|
2
|
4
|
4
|
5
|
9
|
10
|
10
|